West Pharmaceutical Services (NYSE:WST) Price Target Raised to $494.00

West Pharmaceutical Services (NYSE:WST) had its price target increased by research analysts at Citigroup from $412.00 to $494.00 in a report issued on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the medical instruments supplier’s stock. Citigroup‘s price objective would indicate a potential upside of 19.69% from the company’s current price.

WST has been the topic of several other reports. Zacks Research lowered shares of West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 12th. KeyCorp increased their price objective on shares of West Pharmaceutical Services from $350.00 to $390.00 and gave the company an “overweight” rating in a research report on Thursday, July 2nd. Morgan Stanley upgraded shares of West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $365.00 to $400.00 in a research note on Tuesday, September 22nd. Evercore reissued an “outperform” rating and set a $425.00 target price on shares of West Pharmaceutical Services in a research report on Monday, July 27th. Finally, BNP Paribas Exane initiated coverage on shares of West Pharmaceutical Services in a research note on Monday, July 13th. They set an “outperform” rating and a $447.00 price target on the stock. Twelve analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $409.67.

West Pharmaceutical Services Stock Down 0.9%

NYSE WST traded down $3.94 during midday trading on Friday, hitting $412.73. 1,062,315 shares of the company traded hands, compared to its average volume of 809,140. West Pharmaceutical Services has a 52 week low of $223.83 and a 52 week high of $438.27. The company’s 50-day simple moving average is $366.60 and its 200-day simple moving average is $312.50. The company has a market cap of $29.05 billion, a PE ratio of 52.85, a price-to-earnings-growth ratio of 2.83 and a beta of 1.13. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.82 and a quick ratio of 2.12.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings results on Thursday, October 29th. The medical instruments supplier reported $2.66 EPS for the quarter, topping the consensus estimate of $2.20 by $0.46. The firm had revenue of $874.50 million during the quarter, compared to analyst estimates of $827.12 million. West Pharmaceutical Services had a return on equity of 20.11% and a net margin of 16.98%. The business’s revenue for the quarter was up 8.7% compared to the same quarter last year. During the same period in the previous year, the company posted $1.96 EPS. As a group, equities research analysts forecast that West Pharmaceutical Services will post 8.92 earnings per share for the current year.

Insiders Place Their Bets

In other West Pharmaceutical Services news, VP Annette Favorite sold 8,135 shares of the company’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $340.81, for a total value of $2,772,489.35. Following the sale, the vice president owned 16,845 shares in the company, valued at approximately $5,740,944.45. This represents a 32.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders sold 15,659 shares of company stock worth $5,443,749 in the last three months. 0.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On West Pharmaceutical Services

Several institutional investors and hedge funds have recently added to or reduced their stakes in WST. BlackRock Inc. purchased a new stake in shares of West Pharmaceutical Services during the second quarter worth about $2,387,990,000. Bank of New York Mellon Corp acquired a new position in shares of West Pharmaceutical Services during the 2nd quarter worth about $733,733,000. Generation Investment Management LLP acquired a new position in shares of West Pharmaceutical Services during the second quarter valued at approximately $728,168,000. Findlay Park Partners LLP acquired a new position in West Pharmaceutical Services in the 2nd quarter valued at $214,196,000. Finally, Legal & General Group Plc acquired a new position in West Pharmaceutical Services in the 2nd quarter valued at $176,138,000. Hedge funds and other institutional investors own 93.90% of the company’s stock.

Trending Headlines about West Pharmaceutical Services

Here are the key news stories impacting West Pharmaceutical Services this week:

• Positive Sentiment: Q3 results exceeded expectations: West reported adjusted earnings of $2.66 per share, above the $2.20 consensus estimate, while revenue rose 8.7% year over year to $874.5 million, surpassing the $827.1 million forecast. West Reports Third-Quarter 2026 Results
• Positive Sentiment: Higher 2026 outlook: Management raised full-year revenue guidance to $3.41 billion-$3.42 billion from $3.345 billion-$3.380 billion and lifted adjusted EPS guidance to $9.38-$9.48 from $8.85-$9.05. West Pharmaceutical Services Raises Annual Outlook
• Positive Sentiment: Strong high-value product demand: High-Value Product Components sales increased 19.7% and accounted for 53% of quarterly sales, supporting margin expansion and confidence in the company’s growth mix. West Pharma Q3 Earnings Rise on HVP Strength
• Positive Sentiment: Barclays raised its price target to $500 from $440 and maintained an “overweight” rating, implying additional upside based on the referenced share price. Barclays Raises West Pharmaceutical Price Target
• Neutral Sentiment: Institutional positioning was mixed, with several large funds adding shares while others reduced or exited positions. Recent insider activity also showed sales rather than purchases, though these transactions may not reflect the company’s operating outlook.
• Negative Sentiment: Valuation remains a risk after the rally, with the stock trading at a high earnings multiple. One analysis also cautioned that declining cash flow may leave the shares overvalued if earnings growth moderates. West Stock Could Be Overvalued

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc develops and manufactures components and delivery systems used in the administration and packaging of injectable medicines and other healthcare products. Its offerings include elastomer closures, seals, syringe components, drug-delivery systems, and other specialized packaging components designed to support the safety, quality, and performance of pharmaceutical products.

The company also provides contract-manufacturing services for pharmaceutical, biotechnology, and medical-device customers.